First In Ventures

Gliknik is a privately held biopharmaceutical company working to ease human suffering by creating new therapies for people living with immune disorders. The company has two novel drugs in clinical trials and others being advanced preclinically.

Mitra Bio specializes in skin epigenetics, providing solutions for aesthetics and skincare as well as pharmaceuticals.

MultiplAI Health is developing ground-breaking RNA-based, AI-driven screening technology in the form of a simple blood test to transform how cardiovascular diseases are diagnosed.

Flight Path Bio is focused on redefining the treatment of infection-associated diseases through precision therapies that target harmful bacteria while preserving healthy microbial communities.

Medic Life Sciences is focused on revolutionizing cancer drug development through the use of CRISPR functional genomics and advanced tumor models to discover novel cancer biomarkers and drug targets.

Lightspeed Bio specializes in 3D tissue imaging and AI-powered digital pathology solutions.

Humacyte is pioneering a platform that enables the investigation, development, and manufacture of bioengineered human tissues and organs that are designed to be universally implantable, off-the-shelf, and regenerative, with the goal of treating a wide variety of diseases, injuries, and chronic conditions.

Broken String Biosciences is at the forefront of enhancing the safety and efficacy of gene editing therapies to enable transformative therapeutics to become a safe reality for patients.

Biotax is a leading provider of cutting-edge technologies and services, offering biological and genomic informatics solutions for pharma companies, hospitals, and medical centers. The company focuses on harnessing natural microbial communities for health, food, agriculture, and climate applications through advanced AI and novel biological capabilities.

Celldom is a live single-cell biology platform that enables the identification of cellular morphology, phenotypes, activity, and molecular profiles in real-time at high throughput. It provides tools for T cell potency testing, drug screening, and precision medicine.

Invests in early-stage life sciences companies, often backing founders when they are no more than an idea.

Fellowship for early-career scientists run by repeat deep-tech founders, prioritizing technical founder quality, for those who've never written business plans, offering up to $1M and not taking IP rights. SciFounders is run by repeat deep-tech founders who previously built Mammoth Biosciences and Conception. The fund is designed for scientists who have never written a business plan and focuses on technical founder quality over trendy ideas, operating as a long-term partner rather than a fixed-cohort program with no formal end date.

ARCH Venture Partners invests at the concept stage, co-founding and building breakthrough life sciences and deep-science platforms directly with university researchers, acting as a company-builder partner to commercialize frontier biology. The firm concentrates its capital on breakthrough life sciences and deep science platforms with a stated mission to catalyze discoveries that prevent, detect, and cure disease.

F-Prime Capital is one of the few large global VC firms that has built over 30 companies from scratch rather than just backing existing startups, drawing on Fidelity's resources to combine deep healthcare and technology expertise with a structured company-formation engine that pulls together academic founders across multiple geographies. The firm operates with sister fund Eight Roads to create one of the broadest cross-border VC footprints, systematically syndicating ideas across the U.S., Europe, China, Japan, India, and Israel while maintaining a distinctive "technical-risk-yes, regulatory-risk-no" filter that avoids heavy regulatory categories like broad antibiotics in favor of rare diseases and gene therapy where FDA pathways are clearer.

Bioscience investor translating grant-funded research into venture-scale companies, with a pipeline centered on engineering biology using robotic cloud labs and computational design for human health and planetary sustainability. The firm grew directly out of a philanthropic grants program at the Thiel Foundation that funded highly speculative science before spinning into a traditional venture fund.